Simple jQuery Dropdowns
Please use this identifier to cite or link to this item: http://repository.li.mahidol.ac.th/dspace/handle/123456789/41289
Title: Treatment outcomes and resistance patterns of children and adolescents on second-line antiretroviral therapy in Asia
Authors: Wasana Prasitsuebsai
Sirinya Teeraananchai
Thida Singtoroj
Khanh Huu Truong
Jintanat Ananworanich
Viet Chau Do
Lam Van Nguyen
Pope Kosalaraksa
Nia Kurniati
Tavitiya Sudjaritruk
Kulkanya Chokephaibulkit
Stephen J. Kerr
Annette H. Sohn
The HIV Netherlands Australia Thailand Research Collaboration
TREAT Asia/amfAR-The Foundation for AIDS Research
Children's Hospital 1
HJF
Children's Hospital 2
National Hospital of Pediatrics Hanoi
Khon Kaen University
University of Indonesia, RSUPN Dr. Cipto Mangunkusumo
Chiang Mai University
Mahidol University
University of New South Wales (UNSW) Australia
Academic Medical Centre, University of Amsterdam
Keywords: Medicine
Issue Date: 1-Aug-2016
Citation: Journal of Acquired Immune Deficiency Syndromes. Vol.72, No.4 (2016), 380-386
Abstract: © 2016 Wolters Kluwer Health, Inc. Background: Data on pediatric treatment outcomes and drug resistance while on second-line antiretroviral therapy (ART) are needed to guide HIV care in resource-limited countries. Methods: HIV-infected children <18 years who were switched or switching to second-line ART after first-line failure were enrolled from 8 sites in Indonesia, Thailand, and Vietnam. Genotyping was performed at virologic failure (VF; HIV-RNA >1000 copies/mL). Cox proportional hazards regression was used to evaluate factors predicting VF. Results: Of 277 children, 41% were female. At second-line switch, age was 7.5 (5.3-10.3) years, CD4 count was 300 (146-562) cells per cubic millimeter, and percentage was 13 (7-20%); HIV-RNA was 5.0 (4.4-5.5) log 10 copies per milliliter. Second-line regimens contained lamivudine (90%), tenofovir (43%), zidovudine or abacavir (30%), lopinavir (LPV/r; 91%), and atazanavir (ATV; 7%). After 3.3 (1.8-5.3) years on second-line ART, CD4 was 763 (556-1060) cells per cubic millimeter and 26% (20-31%). VF occurred in 73 (27%), with an incidence of 7.25 per 100 person-years (95% confidence interval [CI]: 5.77 to 9.12). Resistance mutations in 50 of 73 children with available genotyping at first VF included M184V (56%), ≥1 thymidine analogue mutation (TAM; 40%), ≥4 TAMs (10%), Q151M (4%), any major LPV mutation (8%), ≥6 LPV mutations (2%), and any major ATV mutation (4%). Associations with VF included age >11 years (hazard ratio [HR] 4.06; 95% CI: 2.15 to 7.66) and HIV-RNA >5.0 log 10 copies per milliliter (HR 2.42; 95% CI: 1.27 to 4.59) at switch and were seen more commonly in children from Vietnam (HR 2.79; 95% CI: 1.55 to 5.02). Conclusions: One-fourth of children developed VF while on second-line ART. However, few developed major mutations to protease inhibitors.
URI: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84977671951&origin=inward
http://repository.li.mahidol.ac.th/dspace/handle/123456789/41289
ISSN: 10779450
15254135
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.